Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of BI 3820768 in advanced germ cell tumours, endometrial cancer, or ovarian cancer
jRCT2031260005Phase 1Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label, single-arm trial of BI 3820768 in germ cell tumor (GCT), endometrial cancer (EC) and ovarian cancer, sponsored by Boehringer Ingelheim. Primary endpoints: Occurrence of treatment-emergent adverse events and Occurrence of dose-limiting toxicities (DLTs). Started Apr 2026; status: recruiting.
02
Drugs
BI 3820768
03
Conditions
germ cell tumor (GCT)endometrial cancer (EC)ovarian cancer
Beyond the preview
Go deeper on jRCT2031260005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260005.